CVS Health raised its 2025 full-year Adjusted EPS guidance to $6.60 to $6.70 from $6.55 to $6.65 and raised total revenues guidance to at least $400.0 billion from at least $397.3 billion.

8-KRegulation FD DisclosureFiled Dec 9, 2025Period of report Dec 9, 2025Summary published (UTC) Oct 12, 2026

Key points

AI summary

CVS Health raised its 2025 full-year Adjusted EPS guidance to $6.60 to $6.70 from $6.55 to $6.65 and raised total revenues guidance to at least $400.0 billion from at least $397.3 billion.
The company initiated 2026 full-year guidance of Adjusted EPS $7.00 to $7.20, GAAP diluted EPS $5.94 to $6.14, total revenues of at least $400.0 billion and cash flow from operations of at least $10.0 billion.
CVS Health presented a reconciliation showing 2025E GAAP operating income of $4,365 to $4,535 million adjusted to adjusted operating income of $14,220 to $14,390 million, with adjustments including goodwill impairment of $5,725 million and legacy litigation charges of $1,220 million.
The company said it expects to achieve a mid-teens Adjusted EPS CAGR through 2028. It also announced at Investor Day the launch of a new technology products and services offering focused on 'Engagement as a Service'.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

2025 Full-Year Guidance Raised

CVS Health raised its 2025 full-year Adjusted EPS guidance to $6.60 to $6.70 from $6.55 to $6.65 and raised total revenues guidance to at least $400.0 billion from at least $397.3 billion.

Source · Based on the filing body and exhibits

2026 Full-Year Guidance Initiated

The company initiated 2026 full-year guidance of Adjusted EPS $7.00 to $7.20, GAAP diluted EPS $5.94 to $6.14, total revenues of at least $400.0 billion and cash flow from operations of at least $10.0 billion.

Source · Based on the filing body and exhibits

2025E Operating Income Reconciliation

CVS Health presented a reconciliation showing 2025E GAAP operating income of $4,365 to $4,535 million adjusted to adjusted operating income of $14,220 to $14,390 million, with adjustments including goodwill impairment of $5,725 million and legacy litigation charges of $1,220 million.

Source · Based on the filing body and exhibits

Mid-Teens Adjusted EPS CAGR Target Through 2028

The company said it expects to achieve a mid-teens Adjusted EPS CAGR through 2028. It also announced at Investor Day the launch of a new technology products and services offering focused on 'Engagement as a Service'.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.